Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is an open-label, multi-center, roll-over study to evaluate the long term safety of ribociclib in combination with other drugs in participants who are participating in a Novartis sponsored global study, that has fulfilled requirements for its primary objective(s), and who in the opinion of the Investigator, would benefit from continued treatment.
Full description
The purpose of this study is to evaluate long-term safety and provide continued treatment to participants who are currently receiving ribociclib in combination with other drugs in a parent study, that has fulfilled requirements for its primary objective(s), and in the opinion of the Investigator, would benefit from continuing treatment at time of discontinuation from the parent study
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key inclusion Criteria:
Key exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply at the end
Primary purpose
Allocation
Interventional model
Masking
137 participants in 1 patient group
Loading...
Central trial contact
Novartis Pharmaceuticals; Novartis Pharmaceuticals
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal